U.S. News & World Report has again ranked Baystate Medical Center among the nation’s top hospitals.
Some are calling the potential of a new class of cholesterol-lowering drugs called PCSK9 inhibitors – now in trial at Baystate Medical Center and being debated by an advisory committee of the Food and Drug Administration, who will vote whether to recommend approval – as “one of the biggest developments in a long time in cardiology.”
Heba Wassif, MD, cardiologist, has recently joined Baystate Medical Practices – Heart and Vascular Program.
Known nationally as a leader in cardiovascular care, Baystate Medical Center was one of only 30 institutions in the U.S. and Europe invited to take part in an important Food and Drug Administration (FDA) trial.
Baystate's Congenital Heart Disease program helps young patients like Christopher, who have congenital heart disease, make the transition from pediatric to adult specialty care.
Baystate is only one of three hospitals in New England to be rated as “high performing” in an analysis of 4,600 hospitals nationwide in U.S. News & World Report's new Best Hospitals for Common Care ratings.